Stockscreener 앱 받기
15.22
0.20%
-0.03
시간 외 거래:
15.22
전일 마감가:
$15.25
열려 있는:
$15.05
하루 거래량:
1.18M
Relative Volume:
1.58
시가총액:
$1.38B
수익:
$802.20M
순이익/손실:
$-155.20M
주가수익비율:
-4.5298
EPS:
-3.36
순현금흐름:
$-141.30M
1주 성능:
-12.07%
1개월 성능:
-34.93%
6개월 성능:
-39.82%
1년 성능:
-14.83%
1일 변동 폭
$14.91
$15.51
1주일 범위
$14.91
$17.45
52주 변동 폭
$14.91
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
명칭
Myriad Genetics Inc
전화
801-584-3600
주소
322 NORTH 2200 WEST, SALT LAKE CITY, UT
MYGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| MYGN | 15.22 | 1.38B | 802.20M | -155.20M | -141.30M | -3.36 |
| TMO | 501.29 | 192.46B | 42.37B | 6.14B | 7.78B | 15.26 |
| DHR | 230.06 | 166.23B | 23.74B | 3.89B | 4.98B | 7.93 |
| A | 126.92 | 36.47B | 6.50B | 1.41B | 1.42B | 3.82 |
| IQV | 191.04 | 34.67B | 15.32B | 1.41B | 1.96B | 5.95 |
| IDXX | 419.83 | 34.38B | 3.84B | 866.24M | 792.60M | 9.80 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-21 | 재개 | Piper Sandler | Neutral |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-07-05 | 재개 | JP Morgan | Underweight |
| 2023-05-23 | 업그레이드 | Goldman | Sell → Buy |
| 2023-01-18 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | 개시 | Stephens | Equal-Weight |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-06-03 | 개시 | Goldman | Sell |
| 2019-09-26 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2019-07-29 | 다운그레이드 | Needham | Strong Buy → Hold |
| 2019-07-09 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-03-12 | 재확인 | Needham | Strong Buy |
| 2019-01-03 | 개시 | Needham | Strong Buy |
| 2018-11-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | 개시 | Goldman | Sell |
| 2018-01-22 | 재확인 | Barclays | Equal Weight |
| 2018-01-05 | 개시 | BTIG Research | Buy |
| 2017-10-02 | 재개 | Leerink Partners | Mkt Perform |
| 2017-08-09 | 재확인 | Barclays | Equal Weight |
| 2017-02-08 | 업그레이드 | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | 개시 | Deutsche Bank | Sell |
| 2016-10-10 | 다운그레이드 | Ladenburg Thalmann | Neutral → Sell |
모두보기
Myriad Genetics Inc 주식(MYGN)의 최신 뉴스
Morgan Stanley Has Lowered Expectations for Myriad Genetics (NASDAQ:MYGN) Stock Price - MarketBeat
71,739 Shares in Myriad Genetics, Inc. (NASDAQ:MYGN) Bought by State of New Jersey Common Pension Fund D - MarketBeat
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
173,626 Shares in Myriad Genetics, Inc. (NASDAQ:MYGN) Purchased by Simplify Asset Management Inc. - MarketBeat
Predictive Genetic Testing & Consumer/Wellness Genomics - GlobeNewswire
MYGN Stock Might Gain From SneakPeek Availability in Retail Stores - Yahoo Finance Australia
Long Term Trading Analysis for (MYGN) - Stock Traders Daily
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch - The Manila Times
Minimal Residual Disease Testing Market Share, Growth Drivers, - openPR
Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price - Simply Wall St
Myriad Genetics stock hits 52-week low at $16.6 amid market shifts - Investing.com Australia
Myriad Genetics Inc (MYGN) Shares Gap Down to $16.76 on Nov 12 - GuruFocus.com
Myriad Genetics: Healthcare Marketing Impact Awards 2024 - Modern Healthcare
How Myriad Genetics helped address the gap in genetic testing among women - Ad Age
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Learn More About the Investigation - AccessWire
Myriad Genetics, Inc. (NASDAQ:MYGN) Q3 2024 Earnings Call Transcript - Insider Monkey
Piper Sandler Has Lowered Expectations for Myriad Genetics (NASDAQ:MYGN) Stock Price - MarketBeat
U.S. Women Health Laboratory Testing Market to Witness - openPR
Global Prostate Cancer Diagnostics Market [2024-2032] | Expected To Grow Across Different Regions Globally - News Channel Nebraska
Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Myriad Genetics Inc (MYGN) Quarterly 10-Q Report - Quartzy
MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View - Yahoo Finance
Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Str - GuruFocus.com
Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Policy ... - Yahoo Finance
Myriad Genetics earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Myriad: Q3 Earnings Snapshot - Marketscreener.com
Myriad Genetics Inc Reports Q3 2024 Revenue of $213 Million, Bea - GuruFocus.com
Compared to Estimates, Myriad (MYGN) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Myriad Genetics (MYGN) Q3 Earnings and Revenues Surpass Estimates - Yahoo Finance
Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Investors to Inquire about Securities Investigation - AccessWire
Pancreatic Cancer Market Expected to Reach $5.7 Billion by 2031 | - openPR
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm - PR Newswire
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announ - WICZ
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Investors to Reach Out - AccessWire
Cancer Diagnostics Market 2024-2031 Product Size Analysis: - openPR
Myriad Genetics holds stock target after UNH update By Investing.com - Investing.com Canada
UnitedHealthcare limits coverage for Myriad's GeneSight test By Investing.com - Investing.com Canada
UnitedHealthcare limits coverage for Myriad's GeneSight test - Investing.com India
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Reach Out - AccessWire
Myriad Genetics (NASDAQ:MYGN) Shares Down 4.6%What's Next? - MarketBeat
Myriad Genetics Inc (MYGN) Trading Down 3.81% on Nov 4 - GuruFocus.com
Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight - MarketWatch
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing - GlobeNewswire
Trading (MYGN) With Integrated Risk Controls - Stock Traders Daily
Myriad weakness due to UnitedHealth coverage update, says Stephens - Yahoo Finance
Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge - Simply Wall St
Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment? - Simply Wall St
Analysts Set Myriad Genetics, Inc. (NASDAQ:MYGN) Target Price at $28.91 - MarketBeat
Myriad Genetics Shares Slip 21% on UnitedHealthcare Coverage Changes - MarketWatch
Myriad Genetics Inc (MYGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.04%
3.19%
자본화:
|
볼륨(24시간):